КЛИНИЧЕСКАЯ ВЗАИМОСВЯЗЬ ОСТЕОПОРОЗА И АТЕРОСКЛЕРОЗА
- Авторы: Шишкова В.Н.1
-
Учреждения:
- ГБУЗ “Центр патологии речи и нейрореабилитации", Москва
- Выпуск: № 2s (2012)
- Страницы: 17-21
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279259
- ID: 279259
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Рассматриваются механизмы развития остеопороза и атеросклероза, сближающие эти заболевания. Представлены данные, свидетельствующие, что остеопороз, кальцификация аорты и клапанов сердца, а также атеросклеротическое поражение сосудов -взаимосвязанные патологические процессы. Подчеркивается, что статины способны благоприятно влиять на костный метаболизм, а бисфосфонаты, напротив, позитивно воздействуют на липидный спектр. Обсуждаются новые подходы к профилактике и лечению остеопороза на основе использования комбинированных лекарственных средств. Таким препаратом, сочетающим мощные антирезорбтивный и анаболический аспекты терапии остеопороза, является Фосаванс, содержащий оригинальный алендронат в дозе 70 мг и витамин D3 в дозе 2800 МЕ.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Вероника Николаевна Шишкова
ГБУЗ “Центр патологии речи и нейрореабилитации", Москвакандидат медицинских наук, старший научный сотрудник
Список литературы
- Braithwaite R.S., Col N.F., Wong J.B. Estimating hip fracture morbidity, mortality and costs. JAGS 2003; 51: 364-70.
- Wenger N.K. Coronary disease in women. Ann Rev Med 1985; 36: 285-94.
- Hamerman D. Bone health across the generations. A primer for health providers concerned with osteoporosis prevention. Maturitas 2004; 50: 1-7.
- Kiel D.P., Kauppila L.I., Cupples L.A., et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 2001; 68: 271-76.
- Frye M.A., Melton L.J., Bryant S.C., et al. Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-94.
- Schulz E., Arfai K., Liu X., Sayre J., Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 4246-53.
- Banks L.M., Macsweeney J.E., Stevenson J.C. Effect of degenerative spinal aortic calcification on bone density measurements in postmenopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest 1994; 24: 813-17.
- Barengolts E.L., Berman M., Kukreja S.C., et al. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998; 62: 209-13.
- Тот П., Мэки К. Нарушения липидного обмена. М., 2010.
- Kado D.M., Browner W.S., Blackwell T., Gove R., Cummings S.R. Rate of bone loss is associated with mortality in older women: A prospective study. J Bone Miner Res 2000; 15: 1974-80.
- Tankoґ L.B., Bagger Y.Z., Christiansen. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003; 73: 15-20.
- Browner W.S., Sooley D.G., Vogt T.M. Non-trauma mortality in eldery women with low bone mineral density. Lancet 1991; 338: 335-38.
- Browner W.S., Pressman A.R., Nevitt M.C., et al. Association between low density and stroke in eldery women. Stroke 1993; 24: 940-46.
- Uyama O., Yoshimoto Y., Yamamoto Y., Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997; 28: 1730-32.
- Van der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106: 273-78.
- Yamaguchi T., Sugimoto T., Yano S., et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002; 49: 211-17.
- Demer L.L. A skeleton in the atherosclerosis closet. Circulation 1995; 92: 2029-32.
- Doherty T.M., Fitzpatrick L.A., Inoue F., et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 2004; 25: 629-72.
- Rubin M.R., Silverberg S.J. Vascular calcification and osteoporosis - The nature of the nexus. J Clin Endocrinol Metab 2004; 89: 4243-45.
- Doherty T.M., Asotra K., Fitzpatrick L.A., et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 2003; 100: 11203-206.
- Frye M.A., Melton L.J. 3rd, Bryant S.C., et al. Osteoporosis and calcification of the aorta. Bone Miner 1992; 19: 185-94.
- Shanahan C.M., Сагу N.R., Metcalfe J.C., et al. High expression of genes for calcification-regulating proteins in human atherosclerotic plaque. J Clin Invest 1994; 93: 2393-402.
- Giachelli C.M., Bae N., Almeida M., et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaque. J Clin Invest 1993; 92: 1686-96.
- Bostrom К., Watson K.E., Hom S., et al. Bone morphogenic expression in human atherosclerotic lesions. J Clin Invest 1993; 91: 1800-09.
- Katsuda S., Okada Y., Minamoto T., et al. Collagens in human atherosclerosis. Arterioscler Thromb 1992; 12: 494-502.
- Parhami F., Morrow A.D., Balucan J., et al. Lipid oxidation oroducts have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation of the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17: 680-87.
- Witztum J.L., Steinberg D. Role of oxidized low density li poprotein in atherogenesis. J Clin Invest 1991; 88: 1785-92.
- Pahmani F., Garfinkel A., Demer L.L. Role of li pids in osteoporosis. Arterioscler Thromb Vasc Biol 2000; 20: 2346-48.
- Watson K.E., Bostrom K., Ravindranath R., et al. TGF-beta and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994; 93: 2106-13.
- Nishizava Y., Morii H. Osteoporosis and atherosclerosis in chronic renal failure. Osteoporosis Int 1997; 7(3): S188-192.
- Stefenelli Т., Mayer H., Bergler-Klein J., et al. Primary hyperparathyroidism: incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993; 95: 197-202.
- Woods А., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000; 21: 1574-83.
- Libby P., Sukhova G., Lee R.T., et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovascular Pharmacol 1995; 25: S9-12.
- Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficiency mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-68.
- Tintut Y., Patel J., Pahmani F., Demer L.L. Tumor necrosis factor- a promotes in vitro calcification of vascular cells via the camp pathway. Circulation 2000; 102: 2636-42.
- Welch G.N., Loscalzo J. Homocystein and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
- Browner W.S., Mallow M.R. Homocysteinemia and bone density in eldery women. Lancet 1991; 338: 1470.
- Werner N., Nickenig G., Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-16.
- Mundy G., Garrett R., Harris S., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-49.
- Wang G.J., Chung K.C., Shen W.J. Li pid-clearing agents in steroid-induced osteoporosis. J Formos Med Ass 1995; 94: 589-92.
- Cui Q., Wang G.J., Su C.C., Balan G. The Otto Aufrance award: lovastatin prevents steroid induced adi pogenesis and osteonecrosis. Clin Ortop 1997; 344: 819.
- Bauer D.C., Mundy G.R., Jamal S.A., et al. Use of statins and fracture. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Ann Intern Med 2004; 164: 146-52.
- Edwards CJ., Russell RGG., Spector DT. Statins and bone: myth or reality? Calcif Tissue Int 2001; 69: 63-6.
- Mundy G.R. Statins and their potential for osteoporosis. Bone 2001; 29: 495-97.
- Hennessy S., Strom B.L. Statins and fracture risk. JAMA 2001; 285: 1888-89.
- Cummings S.R., Bauer D.C. Do statins prevent both cardiovascular disease and fracture? JAMA 2000; 283: 3255-57.
- Adami S., Braga V., Guidi G., et al. Chronic intravenous aminobisphosphanate therapy increases high-density li poprotein cholesterol and decrease low-density cholesterol. J Bone Min Res 2000; 15: 599-604.
- Rogers M.J., Frith J.C., Luckman S.P., et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24: 73-9S.
- Maksymowych W.P. Bisphosphonates for arthritis. A confusing rationale. J Rheumatol 2003; 30: 430-33.
- Danenberg H.D., Golomb G., Groothuis A., et al. Liposomal alendronate inhibits systemic innate immunity and reduces in stent neointimal hyperplasia in rabbits. Circulation 2003; 108: 2798-804.
- Price PA., Faus SA., Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21: 817-24.
- Tanko L.B., Qin G., Alexandersen P., Bagger Y.Z., Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2004; 16: 184-90.
- 53. Шишкова В.Н. Ожирение и остеопороз // Остеопороз и остеопатии 2011. № 1. С. 21-6
Дополнительные файлы
![](/img/style/loading.gif)